FibroBiologics, Inc. (FBLG) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, FibroBiologics reported revenue of $0. Net income was -$18.6M, or -$8.40 per diluted share. Operating activities generated -$16.4M of cash, leaving -$16.7M of free cash flow. At fiscal year end, FibroBiologics held $9.6M in total assets against $3.5M in total liabilities, including $4.9M of cash and equivalents.
Open the full interactive FibroBiologics financials → Quarterly statements, key ratios, valuation history and price charts.
FibroBiologics Key Stats
| Share Price | $0.96 |
|---|---|
| Market Cap | $6.0M |
| 52-Week Range | $0.63 – $9.00 |
| Shares Outstanding | 6.3 million (basic, 2026 Q2) |
FibroBiologics Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating Income | -$8.9M | -$13.7M | -$16.6M |
| Pre-Tax Income | -$16.5M | -$11.2M | -$18.6M |
| Income Tax | $0 | $0 | $0 |
| Net Income | -$16.5M | -$11.2M | -$18.6M |
| Diluted EPS | -$13.60 | -$6.80 | -$8.40 |
FibroBiologics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$5.8M | -$3.2M | -$5.0M | -$4.1M |
| Diluted EPS | -$2.60 | -$0.07 | -$1.33 | -$0.66 |
FibroBiologics Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $9.2M | $14.0M | $4.9M |
| Current Assets | $9.2M | $14.2M | $6.3M |
| Total Assets | $11.8M | $16.4M | $9.6M |
| Current Liabilities | $9.2M | $12.7M | $1.8M |
| Total Liabilities | $10.6M | $13.7M | $3.5M |
| Shareholders' Equity | $1.3M | $2.7M | $6.2M |
FibroBiologics Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$6.4M | -$11.9M | -$16.4M |
| Cash From Investing | -$495,000 | -$184,000 | -$262,000 |
| Cash From Financing | $13.8M | $16.9M | $7.6M |
| Free Cash Flow | -$6.9M | -$12.1M | -$16.7M |
Figures from FibroBiologics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full FibroBiologics financials page for every line item.
FibroBiologics Company Profile
| Ticker | FBLG |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Houston, Texas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001958777 |
Frequently Asked Questions
What was FibroBiologics' revenue in fiscal 2025?
FibroBiologics (FBLG) reported revenue of $0 for fiscal 2025.
What is FibroBiologics' annual revenue history?
FibroBiologics' annual revenue by fiscal year: 2023: $0; 2024: $0; 2025: $0.
What was FibroBiologics' net income in fiscal 2025?
FibroBiologics reported net income of -$18.6M for fiscal 2025.
What was FibroBiologics' earnings per share (EPS) in fiscal 2025?
FibroBiologics' diluted EPS was -$8.40 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did FibroBiologics generate in fiscal 2025?
FibroBiologics generated -$16.7M of free cash flow in fiscal 2025.
What was FibroBiologics' revenue last quarter?
In its most recent reported quarter (2026 Q2), FibroBiologics reported revenue of $0.
How many shares of FibroBiologics are outstanding?
FibroBiologics reported a weighted average of 6.3 million basic shares outstanding in 2026 Q2.
What is FibroBiologics' market cap?
Based on its latest closing price, FibroBiologics (FBLG) has a market capitalization of about $6.0M.
When does FibroBiologics' fiscal year end?
FibroBiologics' fiscal year end, as registered with the SEC, is December 31.
Where is FibroBiologics headquartered?
FibroBiologics lists its business address in Houston, Texas in its SEC filings.